The average price reduction of these drugs is 48%, and the seventh batch of national drug collection is deeply interpreted

On July 13, the National Organization Pharmaceutical Cooperative Procurement Office issued the "Public Announcement of the results of the National Pharmaceutical Concentrated Procurement Procurement", marking the end of the seventh batch of centralized procurement of drugs for drugs.

According to the information of the State Medical Insurance Bureau, the collection of 60 drugs in this collection is successful. The average price reduction of drugs is planned to be selected by 48%. According to the agreed purchase volume, it is expected that the cost can be saved by 18.5 billion yuan each year.

Different from the "national team" soul negotiations that are familiar with everyone, the national drug collection is independently quoted by the enterprise, bidding in the same variety, and there is another set of operation methods. Jingshe Jun takes you to hit the national medicine collection.

Continue to expand: involved 31 treatment categories, and the people who have obtained mild price reduction will not be discounted

Pharmaceutical collection is in exchange for the actual clinical needs of medical institutions in exchange for pharmaceutical companies to provide drugs at lower prices. Therefore, the purchasing volume of each collection and varieties will be adjusted according to clinical needs. This collection involves 31 treatment categories, including common diseases such as hypertension, diabetes, anti -infection, digestive tract diseases, and major diseases such as lung cancer, liver cancer, kidney cancer, and bowel cancer. According to the pre -mining price, calculated that this time, the amount of 294 drugs in seven batches of collection involved about 35%of the procurement of chemical drugs and biopharmaceuticals in public medical institutions. This means that concentrated volume procurement has become an important model for drug procurement of public hospitals.

Gu Hai, director of the Nanjing University Health Policy and Management Research Center, told reporters that the first five batches of collection involved 218 chemical drugs, covering hypertension, coronary heart disease, diabetes, anti -allergy, anti -infection, digestive tract diseases, anti -tumor and other common common Diseases, chronic diseases, major illnesses, and rare diseases; the sixth batch of drugs for the first time from chemicals to the field of biopharmaceuticals, incorporating 16 second- and third generation insulin into the scope of collection; six batches of gastrointestinal metabolism, anti -infection infection, anti -infection infection The number of nervous systems, cardiovascular systems, and anti -tumor medications are included. This time, it continued to expand on the original basis. It can be said that the masses have wider benefits.

Compared with the average rate of 53%of the first six batch of national collection prices, the average price reduction of drugs in this plan is 48%, which is "mild" in the eyes of some people. In this regard, the relevant person in charge of the State Medical Insurance Bureau believes that the reason is from three aspects: First, in recent years, the medical insurance department has strengthened price governance and generally speaking, the prices of drug prices in various provinces are more transparent. Second Some varieties of this collection have been incorporated into local collection, and the price level before the national collection has declined. Third, after multiple rounds of collection, corporate competition is more rational.

Although the price reduction is slightly plain, the sense of acquisition of the masses will not be discounted in the future. This collection not only incorporates more new drugs, but also has a large price of some medicines.

Taking the first -line liver cancer -targeted Yaolunbutoni capsule as an example, each drop from an average of 108 yuan to an average of 18 yuan, and a healing cycle can save 8,100 yuan. In the field of lowering blood pressure, for the first time, it was included in the slow -controlled release agent. The price of nifedine horizontal control was 58%reduced, and the price of Matolol's slow -release tablet was 53%. The burden on the medication of patients with hypertension was significantly reduced. Anti -virus drug Osdivir's per tablet decreased from 4.5 yuan to 1 yuan. In addition, Pfizer's Donalin, Japan's Anstelai Mikafen Pure, Emmiro of Spain, Emmoro, and Bryko Xinyi, Italy, etc. 4 original research medicines In the election, the average price was reduced by 67%.

This time, the average variety of drugs was selected by 5.4 companies, and the supply of diversification and stability was further enhanced. According to the arrangement of the State Medical Insurance Bureau, patients are expected to use the medicines selected in November this year.

Rules upgrade: Strengthen the responsibility of performance, prevent private bargaining the bid for private bargaining

After six episodes, the collection rules have also been slightly adjusted. The consideration is more thoughtful and the operability is stronger. Chang Feng, Dean of the International Medical Business School of China Pharmaceutical University, summarizes the upgrade of the collection rules into five highlights, including a more scientific proportion, "one province and double supply" guarantee supply, splitting the difference between the fuse of the product, the scope of approval management Standards, policy collaboration continues to deepen, and so on.

From the perspective of more scientific perspective, for example, in this national collection, the proportion of antibiotics is 10%compared with the proportion of ordinary drugs, and special -class antibiotic drugs have been further reduced. Policy coordination of medical insurance and health and health departments.

The upgrade of this rule is the establishment of the "one province and double confession" model. In recent years, the incidents of collecting bidding companies have repeatedly occurred. For example, in August 2021, North China Pharmaceuticals interrupted the third batch of collecting varieties of ibuprofen in Shandong, which had a harsh social impact.

"Clinical medication must ensure continuity. Once the enterprise is disconnected, it will affect the treatment of patients. This must be solved in the national collection." Gu Feng told reporters that "one province and double confession" not only strengthened the responsibility of corporate performance, but also Provide "dual insurance" for patients -even if the main supply of enterprises is disconnected, the vice -supply enterprise will be connected soon. Chang Feng believes that "one province and double confession" provides a more secure and direct means to meet the demand for market supply, and can also effectively reduce the administrative cost of the provinces to choose a substitute enterprise.

On July 12, at the quotation site of cephalosporin sodium injection, the four pharmaceutical companies were directly out of the situation because of the price higher than the lowest price of 1.8 times higher than the lowest price and low bid. This time the new rules of the collection "inter -inter -offer" are compared at the same level of different varieties. To a certain extent, it has increased the difficulty and uncertainty of the enterprise's quotation considerations and uncertainty. The maximum is likely to restrict a small number of enterprises of similar varieties in private. bargain. Ensuring fairness is not only reflected in the "interception of inter -grade melting", the management department noticed that the use of effective registration batch of malicious and free transfer may bypass the rules of the associated enterprises to form a siege. "The connotation is widened to prevent some companies from drilling in the process of collection.

Integrated competition: More varieties competitors are more, and companies look forward to stable collection policies

On July 12, Nanjing was hot. There are more than an hour before the start time of the National Pharmaceutical Purchase Reporting Information Disclosure Conference, and more than half of the venue has been filled. The waiter walked beside each attendant and had two small breads outside the mineral water. At this time, the reporter did not understand the meaning of this operation. It was not until the meeting until noon until noon, and found that everyone did not have free lunch.

"There is no bottom in my heart." The reporter asked several companies, and the answers received were exactly the same. This time, the total sales of public medical institutions in public medical institutions were about 70 billion yuan last year. Which company can be willing to lose such a market? However, there are 295 companies participating in the enterprise, and there are more competitors in a single variety. There are more than 10 quotes in 14 varieties. Therefore, how to quote the strength and wisdom of the enterprise.

Photo by Sun Xiuyan

"Phosphate Osci Weil Capsule, 75 mg multiplied by 30 capsules/box, Guangdong Dongguang Pharmaceutical Co., Ltd., 29.97 yuan." On the podium, Qifeng personally enlisted the company's quotation, and read out the name, dosage form and dosage form, and Quotation, notary and supervisors are listed on both sides to supervise the entire process.

488 products in 295 companies participated in the bidding. This procedure was repeated, making the layman feel very boring. However, the scene has always been very quiet, and the company's representatives are highly concentrated, and constantly record and calculate, and the air is filled with tension.

"Can you send a circle of friends?" The offer just ended, but it has not been announced. It is mistaken for the reporter's company representatives to be happy -according to the announcement of the quotation, he knows it!

This time, 327 products from 217 companies were qualified for selection. Among them, 6 of the six international pharmaceutical companies were selected, and 211 domestic pharmaceutical companies were selected as 321 products, and the proportion of bidding companies was 73%. The competition is fierce and the selection is worth celebrating. After the results of the day were announced, many listed companies announced the good news of the selection. However, even if the bid is won, some people are happy and worrying.

"Do not participate in the collection of collection, that is, one is a dead end, and the profit has been falling, and we are also confused." A small -scale pharmaceutical company represents a big deal.

However, in the face of whether the reporter's cost pressure is high, the representative of Hunan Warner Pharmaceutical Co., Ltd., who is the lowest price of the Macaohophen, is full of confidence. "The last time we chose it, and the supply has been stable, we have confidence to do better!"

"Before the collection, we have to face more than 100,000 pharmacies in thousands of hospitals. After the collection, customers are more concentrated. We have the energy to focus on research and development and production." A domestic header of drug companies told reporters that at present, domestic domestic, domestic domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic, domestic. Nearly 5,000 pharmaceutical manufacturers, collection is a process of survival of the fittest, which can guide the industrial concentration and move towards higher quality development. Speaking of the future, the representative said: "We look forward to the collection of policy stability, so that companies can plan for a longer -term vision."

(Source: People's Daily Economic and Social WeChat public account)

【Edit: Fu Sakura】

For more exciting content, please download the "Da Wuhan" client in the major application markets.

- END -